Goodsurance

Costs & IRMAA

Three Compounding Forces Are Likely to Push Medicare Part D Premiums Higher for 2027

Rising drug spending, a new cap that shifted more cost from patients to insurers, and the end of a federal stabilization subsidy are all bearing down on Part D premiums heading into the 2027 enrollment season. Analysts say beneficiaries should compare plans rather than renew automatically.

By the Goodsurance editorial teamSeptember 23, 2026

Medicare beneficiaries shopping standalone Part D drug plans this fall should expect higher premiums in 2027, a KFF Health News analysis published August 25, 2026 found. Three separate factors are pushing costs upward at the same time.

The first is a sustained increase in drug spending. Insurer costs for prescription drugs grew more than 10 percent in 2024, driven in part by rising use of GLP-1 weight-loss medications and high-priced specialty drugs for autoimmune conditions. Because premiums are built on projected future costs, plans carrying heavier drug spending tend to set higher premiums to stay solvent.

Three reasons Medicare Part D premiums are rising for 2027, and why experts say not to auto-renew your drug plan.

The second factor is the Inflation Reduction Act's cap on annual out-of-pocket drug costs for Medicare enrollees, set at 2,000 dollars starting in 2025. While the cap reduced what people with high drug expenses pay directly, it shifted more of the financial exposure to Part D plan sponsors. Plans that absorb more risk tend to raise premiums to offset it.

The third factor is the expiration of the Part D Premium Stabilization Demonstration, a voluntary federal program that provided financial support to standalone drug plans during the rollout of the Inflation Reduction Act's changes. The demonstration, which limited how much premiums could rise in 2025 and 2026, ends after this year. Without it, some enrollees may see notably larger increases than in prior years.

A health policy expert quoted in the KFF Health News analysis advised that beneficiaries should not roll over their current plan without comparing alternatives. Premiums and formulary structures can vary significantly across plans in the same area, and a plan that was optimal last year may no longer be the best fit.

In plain words

Medicare drug plan premiums are expected to be higher in 2027. Three things are causing this at the same time. First, the cost of drugs, including weight-loss medicines, went up more than 10 percent. Second, a new rule limits how much you pay out of pocket to 2,000 dollars a year. That is good for patients, but it means plans pay more and may charge higher premiums to cover it. Third, a government program that held premiums down is ending. Experts say you should not just let your plan renew without checking other options during open enrollment.

Source: KFF Health News
Read at the source →

More news

Other stories on what is moving in Medicare.

Costs & IRMAA

Medigap Plan G Premiums Are Rising Faster Than Usual, With Some Rates Up More Than 26 Percent in 2026

With open enrollment weeks away, rate filings show Plan G increases of 12 to 26 percent or more for major carriers, leaving beneficiaries weighing fewer low-cost switching options.

September 22, 2026

Costs & IRMAA

CMS Posts Preliminary 2027 Medicare Lab Payment Rates, Projects 1 Billion Dollars in Annual Savings

New draft rates would cut what Medicare pays for most laboratory tests by an average of about 16 percent starting in 2027, with a public comment window open through late October.

September 22, 2026

Costs & IRMAA

Medicare Advantage Drug Deductibles Tripled in Two Years, KFF Data Shows

The share of Medicare Advantage drug plan enrollees who face a prescription drug deductible climbed from 23 percent in 2024 to 82 percent in 2026, and the average deductible rose from 64 dollars to 371 dollars over the same period.

September 20, 2026

Costs & IRMAA

Medicare Rehab Hospital Rules Change October 1, Requiring All Therapy to Begin Within 36 Hours of Admission

The FY 2027 inpatient rehabilitation facility rule takes effect in 13 days, extending the 36-hour therapy-start deadline to all prescribed treatments, not just some. Medicare payments to these facilities rise by 2.3 percent, and a rural payment adjustment is fully eliminated for certain facilities.

September 18, 2026

Costs & IRMAA

Medicare Advisory Panel Meets Today and Tomorrow to Help Set 2027 Payment Rates for New Diagnostic Lab Tests

The Advisory Panel on Clinical Diagnostic Laboratory Tests convenes today to recommend whether new lab tests with no market pricing data should be crosswalked to an existing Medicare rate or gapfilled. CMS plans to post proposed payment determinations in late September, with final rates taking effect January 1, 2027.

September 15, 2026

Costs & IRMAA

GAO Urges Congress to Overhaul Medicare Hospice Payments, Citing an Estimated 7.6 Billion Dollar Overspending Gap Over Three Years

A June 2026 federal audit found that Medicare's flat daily hospice rate effectively paid low-visit programs about twice as much per visit as high-visit ones, costing billions more than a visit-based approach would have over a three-year period.

September 13, 2026